ASH 2023 | The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the Phase III Iskia trial (NCT04483739) comparing isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRd) to carfilzomib, lenalidomide, and dexamethasone (KRd) as pre-transplant induction treatment for patients with multiple myeloma (MM). The study reveals that incorporating the antibody isatuximab improves rates of measurable residual disease (MRD) negativity post-transplant, irrespective of risk status, age, or stage. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Incyte Corporation
